论文部分内容阅读
目的探讨非霍奇金淋巴瘤并病毒性乙型肝炎临床诊治。方法 2001年6月至2009年1月收治的非霍奇金淋巴瘤316例为非霍奇金淋巴瘤组,选取同期316例进行体检健康人群为健康对照组。对两组进行HBV检测,并进行HBV感染发生率比较;观察非霍奇金淋巴瘤治疗效果。结果 112非霍奇金淋巴瘤并病毒性乙型肝炎经恩替卡韦治疗后24周,患者按期继续化疗87例,继续化疗率77.67;因肝功能恶化而化疗中断25例,化疗中断率22.33。结论非霍奇金淋巴瘤乙型肝炎感染发生率高,应用恩替卡韦可以达到良好的效果。
Objective To investigate the clinical diagnosis and treatment of non-Hodgkin’s lymphoma with viral hepatitis B. Methods A total of 316 non-Hodgkin’s lymphoma patients admitted to our hospital from June 2001 to January 2009 were non-Hodgkin’s lymphoma patients. 316 healthy controls were selected as healthy controls. HBV test was performed on both groups, and the incidence of HBV infection was compared. The therapeutic effect of non-Hodgkin’s lymphoma was observed. Results 112 non-Hodgkin’s lymphoma and viral hepatitis B after entecavir treatment for 24 weeks, 87 patients continued to chemotherapy on schedule, continue the chemotherapy rate of 77.67; due to deterioration of liver function and chemotherapy in 25 cases interrupted, the chemotherapy interruption rate of 22.33. Conclusions The incidence of hepatitis B in non-Hodgkin’s lymphoma is high. Application of entecavir can achieve good results.